Stock Mover of The Day: What’s Acorda Therapeutics Inc Upside After Today’s Huge Increase?

Stock Mover of The Day: What's Acorda Therapeutics Inc Upside After Today's Huge Increase?

The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) is a huge mover today! About 496,692 shares traded hands. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 30.01% since April 21, 2016 and is downtrending. It has underperformed by 35.34% the S&P500.
The move comes after 8 months positive chart setup for the $1.01 billion company. It was reported on Nov, 23 by We have $23.09 PT which if reached, will make NASDAQ:ACOR worth $70.70M more.

Analysts await Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings on February, 9. They expect $-0.13 earnings per share, down 161.90% or $0.34 from last year’s $0.21 per share. After $-0.28 actual earnings per share reported by Acorda Therapeutics Inc for the previous quarter, Wall Street now forecasts -53.57% EPS growth.

Acorda Therapeutics Inc (NASDAQ:ACOR) Ratings Coverage

Out of 2 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Acorda Therapeutics has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. As per Tuesday, August 25, the company rating was maintained by Cowen & Co. The rating was maintained by JP Morgan with “Neutral” on Tuesday, August 25. The firm earned “Buy” rating on Tuesday, September 1 by Aegis Capital. TheStreet downgraded the stock to “Buy” rating in Tuesday, August 25 report. The company was initiated on Tuesday, September 1 by Raymond James. The rating was maintained by Aegis Capital with “Buy” on Wednesday, January 6. On Tuesday, August 25 the stock rating was maintained by Stifel Nicolaus with “Buy”. Goldman Sachs initiated the stock with “Neutral” rating in Wednesday, March 30 report.

According to Zacks Investment Research, “Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company’s lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.”

Insitutional Activity: The institutional sentiment decreased to 0.89 in 2016 Q2. Its down 0.24, from 1.13 in 2016Q1. The ratio turned negative, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.
Whittier Tru has 33,511 shares for 0.04% of their US portfolio. The Wisconsin-based Convergence Prtnrs Limited Liability Corp has invested 0.07% in Acorda Therapeutics Inc (NASDAQ:ACOR). Deutsche Bancorporation Ag reported 216,914 shares or 0% of all its holdings. Marshall Wace Llp has 35,931 shares for 0.01% of their US portfolio. Guggenheim Cap Ltd Liability Corp last reported 0.01% of its portfolio in the stock. Senzar Asset Mgmt Limited Liability Company accumulated 358,191 shares or 0% of the stock. Alps Advsrs has invested 0.01% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR). Teachers Retirement Systems Of The State Of Kentucky last reported 23,970 shares in the company. Blackrock Group Limited accumulated 87,438 shares or 0% of the stock. Martingale Asset Mgmt Limited Partnership has 0% invested in the company for 11,092 shares. Dimensional Fund Advsrs Ltd Partnership reported 1.35M shares or 0.02% of all its holdings. California Pub Employees Retirement Sys has 88,900 shares for 0% of their US portfolio. Moreover, Millennium Mngmt Limited Company has 0.03% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 565,729 shares. Acadian Asset Mgmt Ltd Liability Corp holds 44,361 shares or 0.01% of its portfolio. Clearbridge Investments Llc reported 944,807 shares or 0.03% of all its holdings.

Insider Transactions: Since June 8, 2016, the stock had 0 insider purchases, and 5 selling transactions for $168,893 net activity. The insider RAUSCHER STEVEN M sold $30,224. 2,063 shares were sold by Batycky Richard P., worth $41,877. Shares for $5,205 were sold by LAWRENCE DAVID. On Friday, September 23 Wasman Jane sold $13,660 worth of the stock or 500 shares.

Another recent and important Acorda Therapeutics Inc (NASDAQ:ACOR) news was published by which published an article titled: “Acorda Therapeutics plummets as much as 13% on failed trial, discontinued drug …” on November 21, 2016.

ACOR Company Profile

Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. The Company’s research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. The Company’s Ampyra (dalfampridine) Extended Release Tablets, 10 milligrams, is used as a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, which are short-acting drugs for the management of spasticity, and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company’s pipeline of neurological therapies addresses a range of disorders, including MS, Parkinson’s disease, chronic post-stroke walking deficits (PSWD), epilepsy and migraine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment